HUP0004967A2 - New crystalline form of nestorone and process for the preparation thereof - Google Patents
New crystalline form of nestorone and process for the preparation thereofInfo
- Publication number
- HUP0004967A2 HUP0004967A2 HU0004967A HUP0004967A HUP0004967A2 HU P0004967 A2 HUP0004967 A2 HU P0004967A2 HU 0004967 A HU0004967 A HU 0004967A HU P0004967 A HUP0004967 A HU P0004967A HU P0004967 A2 HUP0004967 A2 HU P0004967A2
- Authority
- HU
- Hungary
- Prior art keywords
- nesztoron
- water
- allotrope
- active
- allotrop
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 2
- CKFBRGLGTWAVLG-GOMYTPFNSA-N elcometrine Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC(=C)[C@](OC(=O)C)(C(C)=O)[C@@]1(C)CC2 CKFBRGLGTWAVLG-GOMYTPFNSA-N 0.000 title 1
- 229950007611 elcometrine Drugs 0.000 title 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 4
- 239000013078 crystal Substances 0.000 abstract 3
- 238000002425 crystallisation Methods 0.000 abstract 2
- 239000003960 organic solvent Substances 0.000 abstract 2
- 239000006071 cream Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000499 gel Substances 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
A novel crystal allotrope of 16-methylene-17-hydroxy-19-norpregn-4-en-3,20-dione-17-acetate (NESZTORON) is prepared as follows, e.g.: (i) at least 99% active NESZTORON of any morphology is dissolved in an organic solvent which is completely or partially miscible with water, for crystallisation; and (ii) the 'B' allotrope of NESZTORON is precipitated out using 0.1-5 times the volume of water. A novel crystal allotrop of 16-methylene-17-hydroxy-19-norpregn-4-en-3,20-dione-17-acetate (NESZTORON) is prepared as follows: (i) at least 99% active NESZTORON of any morphology is dissolved in an organic solvent which is completely or partially miscible with water, for crystallisation; (ii) the 'B' allotrop of NESZTORON is precipitated out using 0.1-5 times volume of water; and (iii) crystals are separated and optionally washed and dried. This novel 'B' allotrope of NESZTORON is formulated into solid or semi-liquid medicinal preparations that contain and release an even distribution of active matter in a given time period. Formulations find intravaginal applications, and in transdermal creams, gels, and plasters.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU0004967A HUP0004967A2 (en) | 2000-12-18 | 2000-12-18 | New crystalline form of nestorone and process for the preparation thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU0004967A HUP0004967A2 (en) | 2000-12-18 | 2000-12-18 | New crystalline form of nestorone and process for the preparation thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
HU0004967D0 HU0004967D0 (en) | 2001-02-28 |
HUP0004967A2 true HUP0004967A2 (en) | 2002-09-28 |
Family
ID=89978862
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0004967A HUP0004967A2 (en) | 2000-12-18 | 2000-12-18 | New crystalline form of nestorone and process for the preparation thereof |
Country Status (1)
Country | Link |
---|---|
HU (1) | HUP0004967A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10632066B1 (en) | 2019-02-01 | 2020-04-28 | The Population Council, Inc. | Method of providing birth control |
WO2020257544A1 (en) | 2019-06-21 | 2020-12-24 | The Population Council, Inc. | System for providing birth control |
WO2022236045A1 (en) | 2021-05-07 | 2022-11-10 | The Population Council, Inc. | Methods of providing birth control |
US11529308B2 (en) | 2019-06-21 | 2022-12-20 | The Population Council, Inc. | System for providing birth control |
-
2000
- 2000-12-18 HU HU0004967A patent/HUP0004967A2/en unknown
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10632066B1 (en) | 2019-02-01 | 2020-04-28 | The Population Council, Inc. | Method of providing birth control |
US10765628B2 (en) | 2019-02-01 | 2020-09-08 | The Population Council, Inc. | Method of providing birth control |
US10780047B2 (en) | 2019-02-01 | 2020-09-22 | The Population Council, Inc. | Method of providing birth control |
WO2020257544A1 (en) | 2019-06-21 | 2020-12-24 | The Population Council, Inc. | System for providing birth control |
US10918649B2 (en) | 2019-06-21 | 2021-02-16 | The Population Council, Inc. | System for providing birth control |
US10925882B2 (en) | 2019-06-21 | 2021-02-23 | The Population Council, Inc. | System for providing birth control |
US10940157B2 (en) | 2019-06-21 | 2021-03-09 | The Population Council, Inc. | System for providing birth control |
US11529308B2 (en) | 2019-06-21 | 2022-12-20 | The Population Council, Inc. | System for providing birth control |
WO2022236045A1 (en) | 2021-05-07 | 2022-11-10 | The Population Council, Inc. | Methods of providing birth control |
Also Published As
Publication number | Publication date |
---|---|
HU0004967D0 (en) | 2001-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5011099A1 (en) | FORMULATIONS POWDER IN STABLE CRYSTAL STATE | |
HUP0103494A3 (en) | Process for intermittent administration use of growth hormone secretagogues for the manufacture of pharmaceutical compositions for intermittent administration and kit comprising thereof | |
NO20053498L (en) | Derivatives of aryl-quinaolin / aryl-2-amino-phenylmethanone that promote parathyroid hormone release | |
CA2327723A1 (en) | Bicyclic hydroxamic acid derivatives | |
CA2196995A1 (en) | Spiro-azabicyclic compounds useful in therapy | |
CA2218929A1 (en) | Compositions in glassy phase, stabilised by a sugar | |
HUP0400781A3 (en) | Process for the crystallization of (r)- or (s)-lansoprazole, the prepared crystalls and pharmaceutical compositions containing them and their use | |
CA2303498A1 (en) | Dioxocyclopentyl hydroxamic acids | |
ATE451123T1 (en) | VAGINAL ADMINISTERED COMPOSITION FOR THE TREATMENT OF UTERINE DYSRHYTHMIA | |
IL149586A0 (en) | Pyrimidine derivatives as selective inhibitors of cox-2 | |
EP0992509A3 (en) | Novel macrolide derivatives | |
RU2001101892A (en) | TESTOSTERONE DERIVATIVE | |
ATE440838T1 (en) | PHARMACEUTICALLY ACTIVE SULFONYLAMINOSIC ACID DERIVATIVES | |
CA2429639A1 (en) | Stable azithromycin monohydrate | |
HUP0004967A2 (en) | New crystalline form of nestorone and process for the preparation thereof | |
HUP0203884A3 (en) | Crystals of an oxyiminoalkanoic acid derivative and their use as antidiabetics and pharmaceutical compositions containing them | |
WO2001090137A3 (en) | NOVEL SOLID BODY FORMS OF MESOPROGESTIN 11β-[4E-(HYDROXYIMINOMETHYL)-PHENYL]-17α-METHOXYMETHYL-17β-METHOXY-ESTRA-4,9-DIEN-3-ONE | |
ES2187483T3 (en) | PROCEDURE FOR THE PREPARATION OF SOLVENT A-LIPOIC ACID. | |
MY129946A (en) | Compound with gastric acid inhibitory effect and process for its preparation. | |
AU2003267551A1 (en) | Thieno-pyrrole compounds as antagonists of gonadotropin releasing hormone | |
CA2460970A1 (en) | Processes for preparing crystalline and amorphous mupirocin calcium | |
UA83081C2 (en) | Remedy based on honey; use and method for obtaining thereof | |
BR9906975A (en) | Compound, use of it, pharmaceutical composition, and process to stimulate the release of growth hormone by the pituitary of a mammal | |
AP9801235A0 (en) | Erythromycin derivatives. | |
PT1218401E (en) | 4-BENZYLAMINOQUINOLINS CONTAINED WITH BILIARY ACID AND ITS HETEROCYCLICS METHODS OF THEIR PRODUCTION MEDICINES CONTAINING THESE COMPOUNDS AND ITS APPLICATION |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HC9A | Change of name, address |
Owner name: RICHTER GEDEON NYRT., HU Free format text: FORMER OWNER(S): RICHTER GEDEON VEGYESZETI GYAR RT., HU |
|
FA9A | Lapse of provisional patent protection due to relinquishment or protection considered relinquished |